Introduction
============

G protein-coupled receptors (GPCRs) play essential roles in physiological processes and are important therapeutic targets ([@B57], [@B57]; [@B53]). The vast majority of the research efforts that have been made to understand GPCR signaling was performed under the assumption that these membrane proteins function as monomers. Contrary to this view, there is now evidence suggesting that many GPCRs form homo- and heteromers at the cell surface ([@B30]; [@B69]; [@B1]; [@B41]; [@B42], [@B43]; [@B67]; [@B85]; [@B6]; [@B32]; [@B62]; [@B60]; [@B61]; [@B75]). At the molecular level, GPCR signaling is hence not only determined by conformational changes induced by agonist binding, but is also allosterically modulated by interactions with other receptors. Further characterization of the influence of receptor--receptor interactions on signaling will be crucial for understanding GPCR function and could lead to development of novel drugs.

A prototypical GPCR heteromer is the one formed by the A~2A~ adenosine receptors (A~2A~R) and D~2~ dopamine receptors (D~2~R) ([@B36]). *In vitro* experiments demonstrated that activation of the A~2A~R reduces D~2~R high affinity binding of agonists, suggesting that allosteric receptor--receptor interactions in the plasma membrane influence D~2~R signaling ([@B29]). This was further supported by the demonstration that the A~2A~R and D~2~R form heteroreceptor complexes with antagonistic receptor--receptor interactions in living cells and in brain tissue ([@B46]; [@B33]). A considerable amount of experimental data, including biophysical, biochemical, chemical neuroanatomical, and behavioral studies support the view that A~2A~R--D~2~R heteromerization plays an important functional role in the basal ganglia ([@B29]; [@B91]; [@B22]; [@B26]; [@B46]; [@B16]; [@B52]; [@B19]; [@B33], [@B37], [@B38]; [@B3]; [@B9],[@B13], [@B14]; [@B67]; [@B27]; [@B20]; [@B25]). The negative allosteric modulation exerted by A~2A~R activation on D~2~R signaling provided one mechanism contributing to the motor activation observed with general adenosine receptor antagonists (e.g., caffeine) and the neuroleptic effects of A~2A~R agonists ([@B34]). For this reason, the A~2A~R--D~2~R heteroreceptor complex represents a new therapeutic target for disorders treated with drugs interacting with the D~2~R, such as neurodegenerative diseases, schizophrenia, and drug addiction ([@B12]). For example, A~2A~R antagonists should *inter alia* enhance dopaminergic signaling by blocking A~2A~R activation by endogenous adenosine in A~2A~R--D~2~R oligomers, thereby reducing the negative allosteric modulation of the D~2~R protomer ([@B35]). This may contribute to the antiparkinsonian effects observed after treatment with A~2A~R antagonists, such as reduction of bradykinesia, motor fluctuations, and dyskinesia associated with chronic L-DOPA treatment ([@B80]; [@B2]).

Despite the thorough characterization of GPCR heteromers by biophysical and biochemical methods ([@B1]; [@B85]; [@B27]; [@B7]; [@B32]; [@B60]; [@B31]), the understanding of the structural basis of GPCR heteromerization and the associated negative and positive cooperativity remains limited. A major advancement in this area was the recent determination of GPCR crystal structures, which enable generation of atomic resolution models for homo- and heteroreceptor complexes. Crystal structures for representative members from the adenosine ([@B58]) and dopamine ([@B18]; [@B87]) receptor families have recently been solved. In addition, a number of class A GPCRs have crystallized as homodimers ([@B65]; [@B89]; [@B38]; [@B59]; [@B47]), providing different plausible orientations of two monomers relative to each other. The rapidly increasing amount of structural data can now contribute to generation of models of GPCR dimers, which could improve understanding of allosteric modulation.

In this work, a combined computational and experimental approach to construct atomic resolution models of GPCR dimers was developed. In order to predict the structure of the A~2A~R--D~2~R heterodimer, regions involved in the interface were identified based on experiments utilizing peptides corresponding to the transmembrane (TM) helices of the A~2A~R and D~2~R. The effects of synthetic peptides corresponding to the seven TM helices of the A~2A~R on A~2A~R--D~2~R heteromerization were assessed using bioluminescence resonance energy transfer (BRET) ([@B7]) and proximity ligation assays (PLAs). Combined with the corresponding BRET data for the seven TM peptides derived from the D~2~R sequence ([@B13]), an initial model of the A~2A~R--D~2~R heteromer was constructed computationally using protein--protein docking. The predicted heterodimer structure was refined using molecular dynamics (MD) simulations. The resulting A~2A~R--D~2~R structure was subsequently used to predict mutations in the dimer interface, which were evaluated experimentally to assess the model.

Materials and Methods {#s1}
=====================

Plasmid Constructs
------------------

The cDNA encoding the human D~2~R, human A~2A~R, and human A~1~R cloned in pcDNA3.1+ were subcloned (without stop codons) in humanized pGFP^2^-N1 (PerkinElmer, Waltham, MA, United States), pEYFP-N1 (Clontech, Germany), and p*R*luc-N3 vectors (Packard Bioscience, Spain). The cDNA encoding human 3xHA-D~2~R cloned in pcDNA3.1+ and human D~2~R cloned in pGFP^2^-N1 (Perkin-Elmer, Spain) were used as template to generate the two mutants, Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^ \[generic GPCR residue numbers indicated in superscript ([@B48])\], by means of the QuickChange^TM^ site-directed mutagenesis kit (Stratagene, Netherlands) following the manufacturer's protocol. The other constructs used have been described previously ([@B9],[@B13]).

Cell Culture and Transfection
-----------------------------

HEK293T cells (American Type Culture Collection, United States) were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM [L]{.smallcaps}-glutamine, 100 units/ml penicillin/streptomycin, and 10% (v/v) fetal bovine serum (FBS) at 37°C in an atmosphere of 5% CO~2~. Cells were plated in 6-well plates at a concentration of 1 × 10^6^ cells/well or in 75 cm^2^ flasks and cultured overnight prior to transfection. Cells were transiently transfected using linear polyethylenimine (Polysciences Inc., United States). Rat primary striatal neuronal cells purchased from QBM Cell Science (Montreal, QC, Canada) were cultured in Neuro basal medium supplemented with 10% FBS, 2 mM GlutaMAX-1, 1 mM sodium pyruvate, 100 U/ml penicillin G, and 100 μg/ml streptomycin and B-27 supplement at 37°C in a humidified 10% CO~2~ environment according to manufacturer's instructions.

TM Peptide Treatment
--------------------

Synthetic peptides, representing each of the TM peptides for the human A~2A~R, were obtained from [@B54], [@B84], [@B83], CASLO (Denmark) or Ana Spec Inc. (CA, United States) with ≥90% purity. The A~2A~R TM-I peptide consisted of residues 8--32 (VYITVELAIAVLAILGNVLVCWAVW); TM-II peptide of residues 43--66 (YFVVSLAAADIAVGVLAIPFAITI); TM-III peptide of residues 78--100 (LFIACFVLVLTQSSIFSLLAIAI); TM-IV peptide of residues 121--143 (AKGIIAICWVLSFAIGLTPMLGW); TM-V peptide of residues 174--198 (MNYMVYFNFFACVLVPLLLMLGVYL); TM-VI peptide of residues 235--261 (LAIIVGLFALAWLPLHIINCFTFFAPD); and TM-VII peptide of residues 267--291 (LWLMYLAIVLSHTNSVVNPFIYAYR). A di, tri- or quatribasic sequence (KK, KKK, or RKKK) was introduced at the N- and C-terminal to ensure incorporation into the plasma membrane of cells, as demonstrated previously ([@B14], [@B15]). The synthetic peptide representing TM-V of the 5-HT~1A~ receptor was described previously ([@B14], [@B10],[@B11]). Immediately before use, the peptides were solubilized in dimethyl sulfoxide (DMSO) and diluted in the corresponding cell culture medium to yield a final concentration of 1% DMSO. We verified that, for each tested concentration of DMSO alone, no effect on cell viability was observed. Cells were incubated with the above mentioned peptides at 37°C for 2 h prior to performing BRET analysis, *in situ* PLA assays or binding assays.

BRET^1^ Assays
--------------

In the BRET^1^ assays, the receptors of interest were fused to either Renilla luciferase (RLuc) or yellow fluorescent protein (YFP). Detection of dimer interactions is based on that RLuc oxidation of the substrate coelenterazine *h* leads to light emission with a peak at 480 nm, which results in excitation of YFP (excitation and emission maxima of 475 and 530 nm, respectively) if the receptors are in close proximity ([@B71]). In the BRET^1^ saturation assays ([@B7]), HEK293T cells were transiently co-transfected with constant amounts (1 μg) of plasmids encoding for D~2~R^Rluc^ and increasing amounts (0.5--8 μg) of plasmids encoding for A~2A~R^Y\ FP^. Forty-eight hours after transfection the cells were rapidly washed twice in PBS, detached, and resuspended in the same buffer. Cell suspensions (20 μg proteins) were distributed in duplicate into 96-well microplates; black plates with transparent bottom (Corning 3651, Corning, Stockholm, Sweden) for fluorescence measurement or white plates with white bottom (Corning 3600) for BRET determination. For BRET^1^ ratio measurement, coelenterazine *h* substrate (Molecular Probes, Eugene, OR, United States) was added at a final concentration of 5 μM. Readings were performed after 1 min and the BRET signal was detected using the POLARstar Optima plate reader (BMG Lab Technologies, Offenburg, Germany) that allows the sequential integration of the signals detected with two filter settings. Transfected HEK293T cells were incubated with 0.1 μM of the A~2A~R TM-V peptide at 37°C for 2 h prior to performing BRET^1^ analysis. Data were then represented as a normalized netBRET^1^ ratio versus the fluorescence value obtained from the YFP, normalized with the luminescence value of D~2~R^Rluc^ expression 10 min after h-coelenterazine incubation. The normalized netBRET^1^ ratio was defined as the BRET ratio for co-expressed Rluc and YFP constructs normalized against the BRET ratio for the Rluc expression construct alone in the same experiment: netBRET^1^ ratio = \[(YFP emission at 530 ± 10 nm)/(Rluc emission 485 ± 10 nm)\] -- cf. The correction factor, cf. corresponds to (emission at 530 ± 10 nm)/(emission at 485 ± 10 nm) found with the receptor-Rluc construct expressed alone in the same experiment. BRET isotherms were fitted using a non-linear regression equation assuming a single binding site, which provided BRETmax and netBRETmax values. The maximal value of BRET (BRETmax or netBRETmax) corresponds to the situation when all available donor molecules are paired up with acceptor molecules.

To assess specificity of the peptides, HEK293T cells were transiently co-transfected with plasmids encoding for D~2~R^Rluc^ or A~2A~R^Rluc^ and A~2A~R^Y\ FP^ (pcDNA ratio 1:1, 1 μg cDNA each). Forty-eight hours after transfection the cells were incubated with 10 μM of the A~2A~R TM-IV peptide, or 0.1 μM of the A~2A~R TM-V peptide, or 0.1 μM of the 5-HT~1A~ TM-V peptide at 37°C for 2 h prior to performing BRET^1^ analysis. The netBRET signal was detected as described above.

In the BRET^1^ competition assays, HEK293T cells transiently co-transfected with constant amounts (1 μg) of plasmids encoding for D~2~R^Rluc^ and A~2A~R^Y\ FP^ were incubated with each of the seven A~2A~R TM peptides at 37°C for 2 h prior to performing BRET^1^ analysis. The netBRET signal was detected as described above.

BRET^2^ Saturation Assays
-------------------------

In the BRET^2^ assays, the receptors of interest were fused to either RLuc or green fluorescent protein 2 (GFP2). Detection of dimer interactions is based on that Rluc oxidation of coelenterazine 400a (DeepBlueC) leads to light emission with a peak at 395 nm, which results in excitation of GFP^2^ (excitation and emission maxima of 400 and 510 nm, respectively) if the receptors are in close proximity ([@B71]). The BRET^2^ saturation assays ([@B7]) were carried out using plasmids encoding for A~2A~R^Rluc^ and either 3xHA-D~2~R^GFP2^, 3xHA-D~2~R^GFP2^(Tyr192Ala^5.41x42^) or 3xHA-D~2~R^GFP2^(Leu207Ala^5.56^/Lys211Ala^5.60^), respectively. Forty-eight hours after transfection, HEK293T cells transiently transfected with constant (1 μg) or increasing amounts (0.12--7 μg) of plasmids encoding for A~2A~R^Rluc^ and either 3xHA-D~2~R^GFP2^, 3xHA-D~2~R^GFP2^(Tyr192Ala^5.41x42^) or 3xHA-D~2~R^GFP2^(Leu207Ala^5.56^/Lys211Ala^5.60^), respectively, were rapidly washed twice in PBS, detached, and resuspended in the same buffer. Cell suspensions (20 μg protein) were distributed in duplicate into the 96-well microplates; black plates with a transparent bottom (Corning 3651) (Corning, Stockholm, Sweden) for fluorescence measurement or white plates with a white bottom (Corning 3600) for BRET determination. For BRET^2^ measurement, DeepBlue*C* substrate (VWR, Sweden) was added at a final concentration of 5 μM, and readings were performed after 1 min using the POLARstar Optima plate-reader (BMG Lab Technologies, Offenburg, Germany) that allows the sequential integration of the signals detected with two filter settings. The netBRET^2^ ratio was defined as the BRET ratio for co-expressed Rluc and GFP^2^ constructs normalized against the BRET ratio for the Rluc expression construct alone: netBRET^2^ ratio = \[(YFP emission at 515 ± 30 nm)/(Rluc emission 410 ± 80 nm)\] -- cf. The correction factor, cf, corresponds to (emission at 515 ± 30 nm)/(emission at 410 ± 80 nm) found with the receptor-Rluc construct expressed alone in the same experiment. The maximal value of BRET (BRET^2^max or netBRET^2^max) corresponds to the situation when all available donor molecules are paired up with acceptor molecules ([@B36]). The specificities of A~2A~R--D~2~R interactions were assessed by comparison with co-expression of A~1~R^Rluc^ and D~2~R^GFP2^.

*In situ* Proximity Ligation Assay
----------------------------------

HEK293T cells transiently co-transfected with constant amounts (1 μg) of plasmids encoding for A~2A~R and D~2~R and rat primary striatal neuronal cells were employed to study the effect of TM peptides on A~2A~R--D~2~R complexes by means of *in situ* PLA. Furthermore, to study the effect of D~2~R mutants on A~2A~R--D~2~R complexes by means of *in situ* PLA, HEK293T cells were also transiently co-transfected with constant amounts (1 μg) of plasmids encoding for A~2A~R and 3xHA-D~2~R or 3xHA-D~2~R(Tyr192Ala^5.41x42^) or 3xHA-D~2~R(Leu207Ala^5.56^/Lys211Ala^5.60^). *In situ* PLA was performed using rabbit polyclonal anti-A~2A~R (Abcam: ab3461 or Millipore: AB1559) and mouse monoclonal anti-D~2~R (Millipore MABN53, clone 3D9) primary antibodies (for quality control of the antibodies, see [@B25]) and the Duolink *in situ* PLA detection kit (Sigma-Aldrich, Sweden), following the protocol described previously ([@B14], [@B8], [@B9]; [@B25]). Primary striatal neuronal cells or transiently co-transfected HEK293T cells were incubated with 10 μM of the A~2A~R TM-IV peptide or 0.1 μM of the A~2A~R TM-V peptide at 37°C for 2 h prior to performing cell fixation with 3.7% formaldehyde solution (Sigma-Aldrich, Stockholm, Sweden). PLA control experiments employed only one primary antibody or cells transfected with cDNAs encoding only one type of receptor. The PLA signal was visualized and quantified by using a TCS-SL confocal microscope (Leica, United States) and the Duolink Image Tool software. High magnifications of the microphotograph were taken and visualized using multiple z-scan projection. It should be noted that if the confocal data acquisition is performed as a multiple z-scan some positive PLA blobs/clusters may appear to be inside the nuclear blue stained DAPI area despite being located on the cytoplasmic membrane.

Cell Surface Receptor Expression and Cellular Localization Analysis by Fluorescence Confocal Microscopy
-------------------------------------------------------------------------------------------------------

HEK293T cells were transiently transfected with constant amounts (1 μg) of plasmids encoding for 3xHA-D~2~R^GFP2^, 3xHA-D~2~R^GFP2^(Tyr192Ala^5.41x42^) or 3xHA-D~2~R^GFP2^(Leu207Ala^5.56^/Lys211Ala^5.60^). Then, cells were fixed in 4% paraformaldehyde for 10 min, washed with PBS containing 20 mM glycine, and mounted in a Vectashield immunofluorescence medium (Vector Laboratories, United Kingdom). Microscope observations were performed with a 40× oil immersion objective in a Leica TCS-SL confocal microscope (Leica, United States).

\[^3^H\]-Raclopride Competition Experiments
-------------------------------------------

\[^3^H\]-Raclopride binding was displaced by quinpirole to determine the proportion of receptors in the high affinity state (RH), the high affinity (K*~i,High~*), and low affinity (K*~i,Low~*) values for the agonist binding sites from competition curves in HEK cells expressing either A~2A~R/3xHA-D~2~R, A~2A~R/3xHA-D~2~R(Tyr192Ala^5.41x42^), or A~2A~R/3xHA-D~2~R(Leu207Ala^5.56^/Lys211Ala^5.60^). Membrane preparations (60 μg protein/ml) were incubated with increasing concentrations of quinpirole (0.001 nM to 1 μM) and 2 nM \[^3^H\]-raclopride (75 Ci/mmol, Novandi Chemistry AB, Sweden) in 250 μl of incubation buffer (50 mM Tris-HCl, 100 mM NaCl, 7 mM MgCl~2~, 1 mM EDTA, 0.05% BSA, 1 mM DTT) and 0.3 IU/ml adenosine deaminase (EC 3.5.4.4, Sigma-Aldrich) for 90 min at 30°C in the presence or absence of 100 nM of the A~2A~R agonist CGS-21680. Non-specific binding was defined by radioligand binding in the presence of 10 μM (+) butaclamol (Sigma-Aldrich, Sweden). The incubation was terminated by rapid filtration Whatman GF/B filters (Millipore Corp, Sweden) using a MultiScreen^TM^ Vacuum Manifold 96-well followed by three washes (∼250 μl per wash) with ice-cold washing buffer (50 mM Tris-HCl pH 7.4). The filters were dried, 5 ml of scintillation cocktail was added, and the amount of bound ligand was determined after 12 h by liquid scintillation spectrometry.

Statistical Analysis
--------------------

The number of samples (*n*) in each experimental condition is indicated in figure legends. When two experimental conditions were compared, statistical analysis was performed using an unpaired *t*-test. Data from the competition experiments were analyzed by non-linear regression analysis. The changes induced by CGS-21680 on RH, K*~i,High~*, and K*~i,Low~* values were compared using one-way ANOVA. A *p*-value ≤ 0.05 was considered significant.

Homology Modeling
-----------------

An atomic resolution structure of the D~2~R was constructed using homology modeling based on a crystal structure of the D~3~ subtype as template (PDB code 3PBL) ([@B18]). A set of 100 homology models was generated with MODELLER v9.10 ([@B79]) based on a manually edited sequence alignment (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**) generated by the GPCR-ModSim webserver ([@B77]). The D~2~R residues Arg31^1.29^-Tyr36^1.34^ were not present in the corresponding region of the template and alpha-helical restraints were added for these to extend TM-I. In addition, 140 residues from the intracellular loop 3 (IL3) of the D~2~R were omitted by introducing a chain break between Arg222^5.71^ and Leu363^6.25^. The ends of helices TM-V and TM-VI, which are connected by the IL3, were treated as independent. Selection of a final homology model was based on the DOPE scoring function ([@B82]), visual inspection, and the metrics available from the Molprobity server ([@B23]).

Protein--Protein Docking
------------------------

A crystal structure of the A~2A~R (PDB code 4EIY) ([@B58]) and the D~2~R homology model were prepared for protein--protein docking with the program HADDOCK2.1 ([@B24]). The protonation states of ionizable residues (Asp, Glu, Arg, and Lys) were set to their most probable states at pH 7. Histidine protonation states were set by visual inspection on the basis of the hydrogen bonding network (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**). Residues in the predicted dimer interface were used to guide protein--protein docking (**Supplementary Table [S2](#SM1){ref-type="supplementary-material"}**). A set of 1,000 configurations of the A~2A~R--D~2~R heterodimer was generated by rigid-body energy minimization. The 200 complexes with the best energy were refined and clustered by HADDOCK. Each A~2A~R--D~2~R complex was refined with MD sampling in the presence of explicit DMSO molecules to mimick the membrane environment. Subsequent to the determination of the first D~2~R crystal structure (PDB code 6CM4) ([@B87]), the protein--protein docking was repeated with the same parameters. In this case, 10,000 configurations of the A~2A~R--D~2~R dimer were generated and 1,000 of these were refined. The resulting models were clustered ([@B76]) based on superimposition to the A~2A~R with a 7.5 Å RMSD cutoff and a minimum cluster size of four members.

MD Simulations
--------------

A model of the A~2A~R--D~2~R complex was prepared for all-atom MD simulations in GROMACS4.5.5 ([@B72]). Prior to the MD simulations, the stretch of residues surrounding Ser197^5.46x461^ in the extracellular tip of TM-V of the D~2~R was modified to preserve the alpha-helical secondary structure present in the D~3~R template, which had slightly unfolded in the HADDOCK optimization of the heteromer complex. The dimer was inserted into a hydrated 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) bilayer in gel phase (equilibrated at 260 K). Water and lipid atoms overlapping with the protein were removed, and the simulation box walls were set to be 12 and 35 Å from the protein atoms in the Z and XY dimensions, respectively. A 0.15 M sodium concentration and neutralization of the system were accomplished by adding 100 sodium and 118 chloride ions to the system. The resulting hexagonal prism-shaped simulation box comprised 145,260 atoms, including 36,889 water and 438 lipid molecules, and had an initial volume of 156 × 156 × 99 Å^3^. MD simulations were performed using the half-e double-pairlist method ([@B17]) to make the Berger parameters employed for the lipids ([@B4]) compatible with the OPLS-AA force field ([@B51]) used for the protein atoms. As a part of the IL3 of the D~2~R was excluded from modeling, C-terminal amide and N-terminal acetyl caps were added to avoid charge--charge interactions between the termini of residues Arg222 and Leu363, respectively. Similarly, the N-termini of both the A~2A~R (Gly5^1x31^) and D~2~R (Tyr34^1x32^) were capped. The system was solvated with SPC waters ([@B50]). Bond lengths and angles for these molecules were constrained with the SETTLE algorithm ([@B63]), whereas the LINCS algorithm ([@B45]) was used to constrain bond lengths of proteins and lipids. Periodic-boundary conditions were applied in the NPT ensemble using the semiisotropic Parinello-Raman barostat ([@B70]) (1 atm, coupling constant of 2 ps, isothermal compressibility constant of 4.5 × 10^-5^ bar^-1^) and the Nose--Hoover thermostat (310 K with three independent coupling groups for proteins, lipids, and water plus ions). Lennard-Jones and coulombic interactions were explicitly considered within a 12 Å cutoff, whereas the particle mesh Ewald method was used for electrostatic interactions beyond that distance ([@B21]). The system was first minimized with the steepest descent algorithm and was then equilibrated using a time step of 2 fs by applying positional restraints only to protein atoms (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}**), which were gradually released during 10 ns. Three replicas with different initial random velocities were initiated from the last snapshot of the equilibration and 100 ns were then performed in each case.

Results
=======

Mapping of the TM Helices Involved in the A~2A~R--D~2~R Heterodimer Interface
-----------------------------------------------------------------------------

Peptides corresponding to TM helices have been found to disrupt receptor--receptor interactions for GPCRs that form oligomers ([@B44]; [@B68]; [@B13], [@B14]; [@B39]; [@B56]; [@B49]; [@B86]). The proposed mechanism of inhibition is that the helices are part of the protein--protein interface and are able to block oligomerization through competition with the other protomer. Structural information could thus be deduced by investigating the effects of the individual 14 TM helices of the two involved GPCRs on dimerization. In previous work, the ability of the TM helices of the D~2~R to disrupt A~2A~R--D~2~R heteromerization was evaluated by means of quantitative BRET^1^ assays ([@B13]). The receptor--receptor interactions between the A~2A~R labeled with YFP (A~2A~R^Y\ FP^) and D~2~R fused to RLuc (D~2~R^RLuc^) were characterized for the inhibition of the BRET^1^ signal by the seven TM helices (TM-I^D2^ to TM-VII^D2^) in concentration-response experiments. Addition of synthetic peptides TM-IV^D2^ and TM-V^D2^ resulted in a clear concentration-dependent reduction of the BRET^1^ signal, leading to a nearly complete blockade at 1 to 10 μM. TM-VI^D2^ also achieved some inhibition at these concentrations, but not to the same extent as TM-IV^D2^ and TM-V^D2^. The remaining four peptides did not significantly influence A~2A~R--D~2~R heteromerization.

In the current work, the BRET^1^ experiments were performed for the seven TM peptides of the A~2A~R (TM-I^A2A^ to TM-VII^A2A^). TM-IV^A2A^, TM-V^A2A^, and TM-VI^A2A^ displayed a concentration-dependent inhibition of the BRET^1^ signal (**Figure [1A](#F1){ref-type="fig"}**). TM-V^A2A^ had the largest effect and A~2A~R--D~2~R dimerization was almost completely blocked at 1 μM. In a BRET saturation assay, TM-V^A2A^ clearly resulted in a significant reduction of the netBRET^1^max values at 0.1 μM (**Figure [1B](#F1){ref-type="fig"}**). TM-IV^A2A^ and TM-VI^A2A^ also reduced the BRET^1^ signal and reached close to full inhibition at 10 and 100 μM, respectively. TM-IV^A2A^ and TM-V^A2A^ were also evaluated by *in situ* PLAs to characterize the disruption of A~2A~R--D~2~R heteroreceptor complexes in transiently co-transfected HEK293T cells (TM-IV^A2A^, TM-V^A2A^) and in rat striatal primary neuronal cell culture (TM-V^A2A^). In line with the BRET^1^ assays, the *in situ* PLA assay showed that the number of clusters of A~2A~R--D~2~R heteroreceptor complexes was reduced upon addition of 10 μM of TM-IV^A2A^ and 0.1 μM TM-V^A2A^ (**Figure [2](#F2){ref-type="fig"}** and **Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}**).

![Effects of A~2A~R TM peptides on A~2A~R--D~2~R interactions. **(A)** The concentration-response effect of the individual A~2A~R TM peptides (TM-I^A2A^ to TM-VII^A2A^) on BRET^1^ signals of A~2A~R--D~2~R heteromers. Values represent percentages of maximal BRET^1^ responses in cells co-transfected with a 1:1 ratio of D~2~R^Rluc^ and A~2A~R^Y\ FP^ (1 μg cDNA each). Data are averages ± SEM; *n* = 6 experiments, 6 replicates (A~2A~R TM peptides I-III and V-VII); *n* = 6--10 experiments, 6 replicates (A~2A~R TM peptide IV). **(B)** Comparison of the effects of TM-V^A2A^ peptide with the vehicle group on the netBRET^1^ max values obtained from BRET^1^ saturation curves for the A~2A~R--D~2~R heteromers. Co-transfected cells were incubated with 0.1 μM of TM-V^A2A^ peptide or vehicle and studied by BRET^1^ saturation assays. Data are averages ± SEM; *n* = 4, eight replicates. ^∗∗∗^(TM-V^A2A^) significantly different compared to vehicle (*P* \< 0.001) by unpaired *t*-test.](fphar-09-00829-g001){#F1}

![Detection of A~2A~R--D~2~R heteroreceptor complexes in transiently co-transfected HEK293T cells by *in situ* PLA. **(A,B,D,E)** The effects of A~2A~R TM peptides TM-IV^A2A^ (10 μM), TM-V^A2A^ (0.1 μM), and vehicle on the *in situ* PLA A~2A~R--D~2~R heteroreceptor complex signals are shown. Red clusters indicated by arrows represent heteroreceptor complexes and nuclei are shown in blue (DAPI). **(C,F)** Quantification of receptor complexes as the average number of PLA blobs (red clusters) per positive cell was determined using a confocal microscope Leica TCS-SL and the Duolink Image Tool software. Data are averages ± SEM (*n* = 5 experiments, 100 cells per experiment). Decreased A~2A~R--D~2~R heteroreceptor complex formation was observed upon cell incubation with TM-IV^A2A^ (10 μM) and TM-V^A2A^ (0.1 μM). These groups are significantly different compared to vehicle (^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01). Statistical analysis was performed by unpaired *t*-test.](fphar-09-00829-g002){#F2}

To evaluate the impact of the interfering peptides on the allosteric modulation within the A~2A~R--D~2~R heteromer, the affinity values for D~2~R agonist quinpirole for D~2~R were examined in \[^3^H\]-raclopride/quinpirole competition assays in HEK293T cells. The high affinity value (K*~i,High~*), the low affinity value (K*~i,Low~*), and the proportion of receptors in the high affinity state (RH) were not significantly altered when cells expressing only the D~2~R were treated with the TM-IV^A2A^ and TM-V^A2A^ peptides compared with the vehicle by one-way ANOVA (**Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}**). The A~2A~R agonist CGS-21680 decreased the affinity of the high affinity component of the D~2~R agonist quinpirole in membrane preparations expressing A~2A~R--D~2~R, but the K*~i,Low~* and RH values were unaffected (**Figure [3](#F3){ref-type="fig"}**). Agonist binding to the high affinity state (K*~i,High~*) was reduced from 1.05 ± 0.36 nM to 583 ± 27 nM by the A~2A~ agonist CGS-21680. Thus, the strong negative allosteric modulation exerted by the A~2A~R agonist on the high affinity state of the wild type D~2~R was validated. In contrast, the allosteric modulation was significantly reduced in the experiments carried out in the presence of the TM-IV^A2A^ and TM-V^A2A^ peptides. TM-V^A2A^ resulted in the strongest effect and there was a complete loss of allosteric modulation (K*~i,High~* = 2.65 ± 0.52 nM). TM-IV^A2A^ also counteracted the effect on the high affinity component, resulting in a K*~i,High~* of 14.69 ± 0.35 nM. No differences in RH and K*~i,Low~* values were observed after the A~2A~R agonist modulation or treatment of TM peptides (**Figure [3](#F3){ref-type="fig"}**).

![Experimental evaluation of TM peptides in radioligand binding assays. **(A)** Competition experiments involving D~2~R antagonist \[^3^H\]-raclopride binding versus increasing concentrations of quinpirole were performed in membrane preparation from HEK cells expressing A~2A~R--D~2~R in the presence of A~2A~R agonist CGS-21680 (100 nM), or A~2A~R agonist CGS-21680 (100 nM) + TM-IV^A2A^ (10 μM), or A~2A~R agonist CGS-21680 (100 nM) + TM-V^A2A^ (0.1 μM), or vehicle. Non-specific binding was defined as the binding in the presence of 10 μM (+)-butaclamol. The binding values (*n* = 3, in triplicate) are given in percent of specific binding at the lowest concentration of quinpirole employed. **(B)** Analysis and presentation of the high affinity values (K*~i,High~*), low affinity values (K*~i,Low~*), and the proportion of D~2~R in the high affinity state (RH). Averages ± SEM are given for three independent experiments performed in triplicate. Statistical analysis was performed by one-way ANOVA followed by Tukey's Multiple Comparison test. ^∗∗∗^Significant difference compared to vehicle (*P* \< 0.001). ^\#\#\#^Significant difference compared to the CGS-21680 treatment (*P* \< 0.001).](fphar-09-00829-g003){#F3}

To investigate the specificity of the A~2A~R TM peptides, BRET^1^ experiments were also carried out for the A~2A~R homodimer with a receptor population labeled with either YFP (A~2A~R^Y\ FP^) or Rluc (A~2A~R^RLuc^), which were compared to the results obtained for the A~2A~R--D~2~R heterodimer. Each peptide was assayed at a single-point concentration of 10 μM (TM-IV^A2A^) or 0.1 μM (TM-V^A2A^) and, interestingly, the results were different for the homo- and heterodimer. As expected, TM-IV^A2A^ and TM-V^A2A^ significantly reduced the population of A~2A~R--D~2~R complexes. However, no significant reduction of the BRET^1^ signal was observed for these two peptides in the case of A~2A~R homodimer. Similarly, the use of a peptide corresponding to TM-V of the serotonin 5-HT~1A~ receptor ([@B14]) did not have any significant effect on the A~2A~R--D~2~R heteromer or A~2A~R--A~2A~R homomer interactions (**Figure [4](#F4){ref-type="fig"}**).

![Effects of TM peptides on A~2A~R--D~2~R and A~2A~R--A~2A~R interactions. Cotransfected cells were incubated with either TM-IV^A2A^ (10 μM) or TM-V^A2A^ (0.1 μM) peptides or a peptide (0.1 μM) derived from TM-V of the serotonin 5-HT~1A~ receptor and studied by BRET^1^. Values represent netBRET responses (Averages ± SEM; *n* = 4, six replicates). Statistical analysis was performed by unpaired *t*-test. ^∗∗∗^*p* \< 0.001 compared to control group.](fphar-09-00829-g004){#F4}

Experiment-Guided Modeling of the A~2A~R--D~2~R Heteroreceptor Complex
----------------------------------------------------------------------

Modeling of the A~2A~R--D~2~R complex was guided by the BRET^1^ data for the 14 TM peptides of the two protomers and dimer interactions observed in crystal structures of GPCRs. No crystal structures were available for heterodimers, but several class A GPCRs have been crystallized in homomeric arrangements, revealing different potential interfaces (**Figure [5A](#F5){ref-type="fig"}**) ([@B65]; [@B89]; [@B38]; [@B59]; [@B47]). The first cluster of observed dimer interfaces mainly involved TM-I, TM-II, and helix VIII and has, for example, been identified in crystal structures of the β~1~ adrenergic ([@B47]), κ- and μ-opioid ([@B38]; [@B59]) receptors. As no effects of TM-I or TM-II on A~2A~R--D~2~R heteromerization were observed in the BRET^1^ assays, this interface was not further considered. A second set of interfaces involving TM-V and either TM-IV or TM-VI has been revealed by, e.g., crystal structures of squid rhodopsin ([@B65]), CXCR4 ([@B89]), μ-opioid ([@B59]), and β~1~ adrenergic ([@B47]) receptors. The synthetic peptides corresponding to the same three helices of the D~2~R and A~2A~R disrupted A~2A~R--D~2~R heterodimerization in the BRET^1^ assays (**Figure [1](#F1){ref-type="fig"}**) ([@B13]). Visual inspection of the TM-IV/V/VI interfaces observed in the crystal structures of the CXCR4, μ-opioid, and β~1~ adrenergic receptors revealed that none of the observed dimers simultaneously involved all three helices to a significant extent. The μ-OR and squid rhodopsin receptor dimers had TM-V/VI and TM-V interfaces, respectively, but not TM-IV, which showed the largest effect among the synthetic peptides derived from the D~2~R. The β~1~ adrenergic receptor had a TM-IV/V interface, but the buried surface area (BSA) was relatively small (450 Å^2^). The CXCR4 receptor structure had strong interactions via TM-V and also involved TM-IV and TM-VI to a smaller extent, resulting in the largest BSA (∼1,100 Å^2^).

![Crystal structures of GPCR homodimers with interfaces involving TM-IV, TM-V, and TM-VI and the model of the A~2A~R--D~2~R heterodimer. **(A)** Crystal structures of squid rhodopsin (sRho) ([@B65]), μ-opioid (μ-OR) ([@B59]), β~1~ adrenergic (β~1~ADR) ([@B47]), and CXCR4 ([@B89]) receptors. All these GPCRs crystallized as homodimers and have a large buried surface area (BSA). **(B)** Model of the heterodimer formed by the A~2A~R (green, crystal structure) and the D~2~R (orange, homology model). All structures are shown from the extracellular point of view and the TM helices involved in the dimerization interface are indicated. **(C)** Representative MD simulation snapshot of the mutated residues of the D~2~R (Top panel: Tyr192^5.41x42^, Bottom panel: Leu207^5.56^/Lys211^5.60^) with side chains of interacting residues shown as sticks.](fphar-09-00829-g005){#F5}

In order to generate a model of the A~2A~R--D~2~R heterodimer, atomic resolution structures for the monomeric forms of each protomer were required. Multiple crystal structures of the A~2A~R in monomeric form were available and the one with the highest resolution, which represented an inactive state conformation, was selected ([@B58]). At the initiation of this study, no crystal structure of the D~2~R was available. Thus, a crystal structure of the D~3~R ([@B18]) was used to generate a set of homology models of the D~2~R in an inactive-like state. Due to the high sequence similarity to the D~3~R, which shared 71% of the amino acids in the TM region with the D~2~ subtype (**Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}**), there was only a small variation among the models generated. The three best models, as judged by DOPE score ([@B82]), were analyzed manually and one of these was selected as a starting point for modeling of the heterodimer. Models of the A~2A~R--D~2~R complex were first generated by structural superimposition of the monomers onto the available homodimer crystal structures with interfaces that involved TM-IV and TM-V. CXCR4 ([@B89]) was considered to be the best template for the A~2A~R--D~2~R heterodimer based on the large contact interface involving TM-V, but the resulting model only had weak interactions with TM-IV. Protein--protein docking with the program HADDOCK ([@B24]) was performed to identify interfaces that were in better agreement with the experimental data for the TM peptides. HADDOCK allows inclusion of experimental data to focus the docking calculation on a specific interface. Residues in TM-IV and TM-V were defined as being involved in the interface based on the BRET data and CXCR4-based model (**Supplementary Table [S2](#SM1){ref-type="supplementary-material"}**). The protein--protein docking was used to generate 200 models of the A~2A~R--D~2~R complex, which were clustered based on RMSD. The 10 most populated clusters are shown in **Supplementary Figure [S4](#SM1){ref-type="supplementary-material"}** and were analyzed based on four criteria (**Supplementary Table [S4](#SM1){ref-type="supplementary-material"}**). The first two criteria required the receptors to be oriented in a parallel manner and correctly aligned with the plane of the membrane-solvent interface, which was fulfilled by 133 models from four different clusters. Among these, the heterodimer models in the sixth cluster were found to have the most extensive contacts involving TM-IV and TM-V and its centroid was selected for further consideration (**Figure [5B](#F5){ref-type="fig"}** and **Supplementary Figure [S5](#SM1){ref-type="supplementary-material"}**). The predicted A~2A~R--D~2~R interface had a total BSA of ∼1,200 Å^2^ and was overall similar, but not identical, to the model obtained by aligning to the CXCR4 homodimer crystal structure (**Supplementary Figure [S6](#SM1){ref-type="supplementary-material"}**). TM-V was the helix with the highest contribution to the dimer interface for both protomers. However, the selected structure had some rearrangements compared to CXCR4-based model that led to higher involvement of TM-IV.

MD Simulation Refinement of the A~2A~R--D~2~R Heterodimer Model
---------------------------------------------------------------

The A~2A~R--D~2~R heterodimer predicted by protein--protein docking was further explored using all-atom MD simulations in a hydrated lipid bilayer. The time-scales reachable by MD simulations are too short to observe major rearrangements of the dimer interface, structural changes related to activation of the receptors, or the influence of oligomerization on ligand binding. Therefore the goal of these calculations was to refine the predicted interface using a more realistic model of the biological environment. Three independent trajectories of the dimer model were generated, resulting in a total of 0.3 μs of unrestrained simulation. After a short equilibration (**Supplementary Table [S3](#SM1){ref-type="supplementary-material"}**), the overall root mean square deviation (RMSD) of the Cα atoms of the dimer increased slightly during the first ∼40 ns of unrestrained simulation and then stabilized at an average of 3.3 Å, which is similar to the results obtained for a simulation study on the crystal structure of the CXCR4 homodimer ([@B78]). The largest structural changes were observed in TM-VII of the A~2A~R and TM-I of the D~2~R whereas the dimer interface remained stable. The BSA changed only slightly during the simulation, with an average of 1,163 Å^2^ for the last 50 ns of the three simulation replicas (**Supplementary Figure [S7](#SM1){ref-type="supplementary-material"}** and **Supplementary Table [S5](#SM1){ref-type="supplementary-material"}**).

Snapshots from the MD simulations were analyzed to identify interactions between specific residues in the interface. To further evaluate the model, two D~2~R mutants that probed interactions in either the N- or C-terminal ends of these helices were predicted (**Figure [5C](#F5){ref-type="fig"}**). The interaction interface at the top of TM-V was close to the orthosteric binding sites of both receptors. Tyr192^5.41x42^ of the D~2~R was located just one helical turn from a set of residues (Ser193^5.42x43^, Ser194^5.43x44^, and Ser197^5.46x461^) that has been proposed to play a role in the activation mechanism for monoamine-recognizing GPCRs ([@B88]). The side chain of Tyr192^5.41x42^ formed stacking interactions with a cluster of aromatic residues formed by Tyr179^5.40x411^ and Phe183^5.44x45^ in TM-V of the A~2A~R, which were located only ∼10 Å from the adenosine binding site. At the intracellular end of TM-V of the D~2~R, interactions with residues in TM-IV and TM-V of the A~2A~R were formed. Leu207^5.56^ of the D~2~R interacted with Ile127^4.48^, Val130^5.51^, and Leu131^4.52^ of the A~2A~R whereas the alkyl chain of Lys211^5.60^ formed van der Waals interactions with Ile127^4.48^ of the A~2A~R. Based on these results, two mutants of the D~2~R, Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^, were predicted to reduce favorable dimer interactions and were selected for experimental evaluation.

Experimental Evaluation of D~2~R Mutations in the Predicted Heteromer Interface
-------------------------------------------------------------------------------

To further probe the predicted role of TM-V of the D~2~R in A~2A~R--D~2~R heteromerization, the Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^ D~2~R mutants were evaluated experimentally in BRET^2^, *in situ* PLA, and binding assays. No differences in cellular localization at the membrane level between the wild type and mutants of the D~2~R were observed (**Supplementary Figure [S8](#SM1){ref-type="supplementary-material"}**). The interactions between the wild type and mutant D~2~Rs labeled with GFP2 with the A~2A~R^RLuc^ were first assessed in BRET^2^ saturation assays. Both the Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^ mutations reduced A~2A~R--D~2~R interactions and the largest effect was observed for the double mutant (*p* \< 0.01, **Figure [6](#F6){ref-type="fig"}**). In contrast, no significant differences were observed between the wild type and mutant D~2~Rs with the A~2A~R protomer if the *in situ* PLA method was used (**Supplementary Figure [S9](#SM1){ref-type="supplementary-material"}**). In binding assays, the high affinity value (K*~i,High~*) for D~2~R agonist quinpirole for 3xHA-D~2~R, 3xHA-D~2~R(Tyr192Ala^5.41x42^), and 3xHA-D~2~R(Leu207Ala^5.56^/Lys211Ala^5.60^) were determined in \[^3^H\]-raclopride/quinpirole competition assays (1.65 ± 0.21 nM, 1.08 ± 0.34 nM, and 1.80 ± 0.22 nM, respectively). The high affinity value (K*~i,High~*), the low affinity value (K*~i,Low~*) and the proportion of receptors in the high affinity state (RH) were not significantly altered for the two D~2~R mutants compared with the wild type D~2~R by one-way ANOVA (**Supplementary Figure [S10](#SM1){ref-type="supplementary-material"}**). As expected, the A~2A~R agonist CGS-21680 decreased the affinity of the high affinity component of the D~2~R agonist quinpirole in membrane preparations expressing A~2A~R/3xHA-D~2~R whereas the K*~i,Low~* and RH values were not significantly altered. The D~2~R agonist binding to the high affinity state was reduced 300-fold by the A~2A~ receptor agonist CGS-21680 to 533 ± 23 nM. Significant A~2A~R agonist induced reductions of the K*~i,High~* value for quinpirole were also observed for the D~2~R mutants, but not to the same degree as found in the wild type. The Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^ mutants had (K*~i,High~*) values equal to 129 ± 21 nM and 90 ± 2 nM in the presence of A~2A~R agonist, respectively. The ability of 3xHA-D~2~R(Tyr192Ala^5.41x42^) and 3xHA-D~2~R(Leu207Ala^5.56^/Lys211Ala^5.60^) to respond to the negative allosteric modulation induced by the A~2A~R agonist was hence significantly lower than for the wild type A~2A~R/3xHA-D~2~R complex. No significant differences in RH and K~i,Low~ values were observed (**Figure [7](#F7){ref-type="fig"}**).

![Experimental evaluation of mutations in the A~2A~R--D~2~R dimer interface by BRET^2^. BRET^2^ saturation curves for the A~2A~R--D~2~R heterodimer for wild type and mutants of the D~2~R. The normalized BRET^2^ ratio, which was defined as the netBRET^2^ ratio for co-expressed Rluc and GFP^2^ constructs normalized against the netBRET^2^ ratio for the Rluc expression construct alone in the same experiment, is plotted on the *y*-axis. The fluorescence value obtained from the GFP^2^, normalized with the luminescence value of A~2A~R^Rluc^ or A~1~R^Rluc^ expression 10 min after *DeepBlueC* incubation, is plotted on the *x*-axis. GFP~0~ is defined as the fluorescent emission values at 515 ± 30 nm of the cells which only expressed the Rluc construct. Data are averages ± SEM; *n* = 5, eight replicates. Statistical analysis was performed by unpaired *t*-test. The netBRETmax values of A~2A~R--D~2~R(Tyr192Ala^5.41x42^) are significantly different compared to A~2A~R--D~2~R (*P* \< 0.05) and the netBRETmax values of A~2A~R--D~2~R(Leu207Ala^5.56^/Lys211Ala^5.60^) are significantly different compared to A~2A~R--D~2~R (*P* \< 0.01).](fphar-09-00829-g006){#F6}

![Experimental evaluation of mutations in the A~2A~R--D~2~R dimer interface by radioligand binding assays. **(A)** Competition experiments involving D~2~R antagonist \[^3^H\]-raclopride binding versus increasing concentrations of quinpirole were performed in membrane preparation from HEK cells expressing A~2A~R/3xHA-D~2~R or A~2A~R/3xHA-D~2~R(T192A^5.41x42^), or A~2A~R/3x-HA-D~2~R(L207A^5.56^/K211A^5.60^) in the presence or absence of A~2A~R agonist CGS-21680 (100 nM). Non-specific binding was defined as the binding in the presence of 10 μM (+)-butaclamol. The binding values (*n* = 4, in triplicate) are given in percent of specific binding at the lowest concentration of quinpirole employed. **(B)** Analysis and presentation of the CGS-21680 induced changes in the high affinity values (K*~i,High~*), low affinity values (K*~i,Low~*) and in the proportion of D~2~R in the high affinity state (RH) after incubation of the membrane preparations with A~2A~R agonist CGS-21680 (100 nM). Data are averages ± SEM of four independent experiments, each one performed in triplicate. Statistical analysis was performed by one-way ANOVA followed by Tukey's Multiple Comparison test. ^∗∗∗^*P* \< 0.001 and ^∗^*P* \< 0.05; Significant difference compared to wild-type without CGS-21680. ^\#\#\#^*P* \< 0.001; The results for the two mutants were significantly different compared to wild-type with CGS-21680.](fphar-09-00829-g007){#F7}

Model of the A~2A~R--D~2~R Complex Based on Crystal Structures of Both Protomers
--------------------------------------------------------------------------------

After the initial review of this paper, the first crystal structure of the D~2~R was determined ([@B87]). This allowed us to assess the accuracy of the D~2~R model and generate alternative interfaces of the A~2A~R--D~2~R dimer using protein--protein docking based on crystal structures of both receptors. Alignment of the D~2~R homology model and crystal structure showed that the D~3~R subtype was a good template for the prediction of the TM region (backbone RMSD = 1.2 Å). To assess the influence of using a D~2~R homology model on our results and to further improve our model of the A~2A~R--D~2~R complex, the protein--protein docking calculations were carried out with the crystal structures. A total of 1,000 models were generated and the resulting clusters of potential interfaces were assessed using the same criteria as for the D~2~R homology model (**Supplementary Table [S6](#SM1){ref-type="supplementary-material"}**). The third most populated cluster was compatible with membrane insertion and had a TM-IV/V interface. The interface RMSD between the cluster center obtained from docking with the D~2~R homology model (cluster 6, **Supplementary Table [S4](#SM1){ref-type="supplementary-material"}**) and crystal structure (cluster 3, **Supplementary Table [S6](#SM1){ref-type="supplementary-material"}**) was 4.6 Å. These models hence belonged to the same cluster of solutions (HADDOCK clustering cut-off \< 7.5 Å) and the interfaces were very similar based on our criteria (**Supplementary Figure [S11](#SM1){ref-type="supplementary-material"}**). On the residue level, there were some differences in the interactions predicted by the two cluster centers, but the contacts made by the residues evaluated by mutagenesis (Tyr192Ala^5.41x42^ and Leu207Ala^5.56^/Lys211Ala^5.60^) were maintained in the A~2A~R--D~2~R complex obtained using the crystal structures (**Supplementary Figure [S11](#SM1){ref-type="supplementary-material"}**). A representative A~2A~R--D~2~R model obtained using crystal structures of both receptors is shown in **Figure [8](#F8){ref-type="fig"}**.

![Model of the A~2A~R--D~2~R heterodimer based on crystal structures of both receptors. The structure of the A~2A~R--D~2~R heteroreceptor complex is based on protein--protein docking with the A~2A~R (green) and D~2~R (orange) depicted as cartoons.](fphar-09-00829-g008){#F8}

Discussion
==========

The main result of this study is that identification of dimer disrupting peptides derived from TM helices in combination with crystal structure data for GPCRs enabled the generation of atomic-resolution models of the A~2A~R--D~2~R heteroreceptor complex. A representative A~2A~R--D~2~R model was refined using MD simulations and mutations in the predicted interface reduced the propensity of the receptors to dimerize.

A key step toward understanding GPCR heteromerization is the identification of the regions involved in receptor--receptor interactions ([@B62]; [@B20]). In the membrane-spanning region, essentially every TM helix has been proposed as a potential interface ([@B81]; [@B28]). For example, in the case of the A~2A~R--D~2~R heteromer, [@B16] proposed that the TM interface was mainly composed of TM-V/VI/VII (D~2~R) and TM-III/IV (A~2A~R) whereas the study by [@B13] predicted that TM-IV/V (D~2~R) interacted with either TM-IV/V (A~2A~R) or TM-I/VII (A~2A~R). In the current work, the interface of the A~2A~R--D~2~R heteromer was further characterized by probing the ability of peptides based on the TM helices of the A~2A~R to interfere with receptor--receptor interactions. The TM-IV and TM-V peptides had the strongest effect on A~2A~R--D~2~R interactions. Combined with the corresponding data for the D~2~R ([@B13]), the results pointed to a primary interface involving TM-IV/V for both the A~2A~R and D~2~R, but may also involve interactions with TM-VI. This model is in agreement with the work of [@B16], in which a chimera of the D~1~- and D~2~R subtypes was characterized. To probe the role of the TM region of the D~2~R in heteromerization, [@B16] replaced TM-V/VI and IL3 with the corresponding sequence of the D~1~ subtype, which does not dimerize with the A~2A~R. The D~2~/D~1~ chimera did not interact with the A~2A~R, supporting a TM interface involving either TM-V, TM-VI, IL3 or a combination of these regions. These results are consistent with our experimental data for peptides corresponding to TM-V of the D~2~R, which resulted in a reduction of heteromerization in BRET assays ([@B13]). As TM-IV, TM-V, and TM-VI cannot be part of a single interface, TM-IV/V interactions were prioritized over those involving TM-V/VI based on the fact that the TM-VI peptide resulted in the smallest effects experimentally. In addition, the fact that the degree of A~2A~R--D~2~R heteromerization is not affected by receptor activation ([@B16]) makes an TM-V/VI interface less likely because this complex would not allow the large conformational changes in TM-VI required for G protein binding ([@B74]). An alternative interpretation is that the dimer interface changes upon activation, as proposed for the D~2~R ([@B40]) and metabotropic glutamate receptor 2 homodimers ([@B90]). Although this is a more complex model, it is possible that there is an equilibrium between the TM-IV/V and TM-V/VI interfaces, which may be influenced by activation of either protomer. The results for the TM peptides and predicted interactions are also in agreement with the recent findings by [@B66], which also identified TM-IV/V as the primary interface of the A~2A~R--D~2~R heterodimer.

With a more detailed map of the helices involved in A~2A~R--D~2~R heteromerization, specific residue interactions and their role in allosteric modulation of ligand binding can be probed. Previous studies have investigated the role of intracellular regions in A~2A~R--D~2~R heteromerization by site directed mutagenesis. Based on pulldown and mass spectrometry experiments, negatively charged residues in the C-terminal tail of the A~2A~R were proposed to form strong interactions with an arginine rich region in IL3 of the D~2~R ([@B19]). Mutagenesis of the set of arginine residues in IL3 of the D~2~R (217--222 and 267--269) to alanine abolished the negative allosteric modulation of D~2~R agonist on activation of the A~2A~R ([@B27]). Similarly, site-directed mutagenesis for three residues in the C-terminal tail of the A~2A~R (Ser374, Asp401, and Asp402) supported a role of this intracellular region in heteromerization. Loss of heteromerization for the alanine mutant of phosphorylated Ser374, the double mutant Asp401Ala/Asp402Ala as well as the combination of these three mutations were demonstrated in BRET assays. The two mutants involving Ser374 also disrupted the negative allosteric modulation mediated by the A~2A~R on high-affinity agonist binding to the D~2~R ([@B9]). The C-terminal of the A~2A~R and IL3 of the D~2~R were not included in our proposed heterodimer model because of the lack of reliable templates to predict these regions. However, it should be noted that the positively charged region in IL3 of the D~2~R is close to our proposed TM-IV/V interface as these residues are located at the intracellular part of TM-V. Considering that the three negatively charged residues of the A~2A~R are located at the end of the long C-terminal tail, interactions between these two regions are also compatible with our proposed model.

To further test the predicted TM interface of the A~2A~R--D~2~R complex, two D~2~R variants with mutations in either the N- or C-terminal end of TM-V were evaluated experimentally. None of these mutations disrupted dimerization completely, which was expected considering the large predicted contact surface and the involvement of intracellular regions in receptor--receptor interactions. The BRET data indicated a reduced population of heteroreceptor complexes, which supports the view that TM-V of the D~2~R is part of the interface. The lack of effect in the PLA experiments may be due to a combination of the relatively modest impact of the mutants on dimerization and high receptor expression, which can lead to saturation effects that influence quantification of small differences in the level of receptor--receptor interactions using this technique ([@B64]). Based on the binding data, the predicted TM-IV/V interactions between the two receptors could contribute to the negative allosteric modulation across the A~2A~R--D~2~R heterodimer. Interestingly, crystal structures of the A~2A~R in active- and inactive-like conformations suggest that TM-V shifts slightly inward upon activation by adenosine ([@B55]). A similar inward contraction of TM-V was observed for monoamine-recognizing GPCRs that are homologous to the D~2~R (e.g., for the β~1~ and β~2~ adrenergic receptors) ([@B73]; [@B88]). The negative allosteric modulation across the A~2A~R--D~2~R heterodimer may thus be partly accomplished via interactions across the TM-V interface. The reduction of agonist binding to the D~2~R observed upon activation of the A~2A~R may be due to altered helix--helix interactions when TM-V shifts inward in response to adenosine receptor activation. In the complex with an A~2A~R antagonist, TM-V can instead contribute to stabilizing the high affinity state conformation of the D~2~R binding site, leading to the increased dopaminergic D~2~R signaling sought in treatment of Parkinson's disease ([@B37]; [@B2]).

The A~2A~R and D~2~R exist both as homo- and heteromers in the brain and alteration of the balance between these receptor complexes influences intracellular signaling and could lead to development of neurological diseases ([@B31]). The heteromer interface between the A~2A~R and D~2~R was the main focus of this work. Future studies need to consider potential changes to the interface upon receptor activation, the influence of homodimers on A~2A~R--D~2~R interactions, and the existence of tetramers composed by A~2A~R--A~2A~R and D~2~R--D~2~R complexes ([@B5]). As a first step toward characterizing the A~2A~R homodimer, the effects of peptides derived from TM-IV and TM-V of the A~2A~R on this complex were evaluated experimentally. In contrast to the strong inhibition of dimerization observed with these peptides for the A~2A~R--D~2~R heteromer, there were no effects on A~2A~R homomerization. The TM-IV^A2A^ and TM-V^A2A^ peptides hence selectively modulate the A~2A~R--D~2~R heteromer, which supports the view that the A~2A~R homo- and A~2A~R--D~2~R heteromerization involve different helices.

In this work, we developed an approach for mapping the interfaces of GPCR dimers based on biophysical experiments in combination with protein--protein docking and MD simulations. The modeling of the A~2A~R--D~2~R heterodimer was guided by information from low-resolution experiments that identified helices involved in receptor--receptor interactions and led to a potential TM-IV/V interface. The proposed A~2A~R--D~2~R structure provides a starting-point for designing new experiments that can contribute to further refinement of the model and understanding of allosteric modulation at the molecular level. The same approach can likely be extended to the large number of class A GPCRs that have been shown to engage in receptor--receptor interactions.
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